Document is current

Article History

Received: 13 December 2025

Accepted: 10 January 2026

First Online: 20 January 2026

Declarations

:

: S.B has received personal compensation from Eli Lilly for oral communications. C.D. has received travel grants and honoraria from AstraZeneca, Merck & Co, Pfizer and Teva Pharmaceuticals and research grants from the International Headache Society and the Hellenic Neurology Society. V.S.T has received travel grants from ECTRIMS and the European Academy of Neurology, as well as coverage of congress registration fees from Inovis, Genesis Pharma and Novartis. A.P.A reports advisory board at Neuresta, Zenith Scientific, Modulight. Speaker/Speaker board at AbbVie, Pfizer, Organon, TEVA. Consultant at Neuresta, Zenith Scientific, General Services Consulting. Grant support for research or education at AbbVie, Pfizer, Ipsen, Medical Research Foundation, Brain Research UK, Migraine Trust, Medical Research Council, National Institute of Health. D.D.M has received fees and travel grants from AbbVie/Allergan, Amgen, Eli Lilly and Company, ELPEN, Genesis Pharma, Lundberg, Merck & Co, Mylan, Novartis, Roche, Sanofi, Pfizer, and Teva Pharmaceuticals. He has also participated in clinical trials for Amgen, Eli Lily and Company, Lundberg, Novartis, Pfizer, and Teva Pharmaceuticals as the principal investigator. D.D.M is also the president of the Hellenic Headache Society and is a member of the Management Group of the Headache Scientific Panel of the European Academy of Neurology. He also served in the past as President of the European Headache Federation. D.D.M has also had commercial assistance and/or received honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Company, Genesis Pharma, Helion, Lundbeck, Merck and Co, Novartis, Orion Pharma, Pfizer, Roche and Teva Pharmaceuticals. T.M Received travel grant from AbbVie. L.K and G.C report no conflicts of interest.